FAKE NEWS, junk science, and alternative facts seem pervasive in our current culture, to the detriment of important, verified scientific advancements. One area where this is quite evident is the vaccine against human papillomavirus (HPV). Although we have had a safe, effective vaccine since...!-->!-->
IMMUNOTHERAPY AND ANTIANGIOGENESIS were highlighted in a session on metastatic non–small cell lung cancer (NSCLC) at the Best of ASCO New Orleans meeting. Matthew Gubens, MD, MS, presented the selected abstracts from the ASCO Annual Meeting.1 Dr. Gubens is Associate Professor of...!-->!-->
ANTAGONISM OF THE ANDROGEN AXIS remains a cornerstone of systemic therapy for high-risk localized and metastatic prostate cancer, reflecting the central role of androgen-dependent biologic mechanisms in hormone-naive disease. Despite the use of standard androgen-deprivation therapy, men...!-->!-->!-->!-->
THE ADDITION of daratumumab (Darzalex) to a triplet induction regimen led to good responses in newly diagnosed multiple myeloma, but not without toxicities. And in the treatment of myeloma bone disease, denosumab (Xgeva) in place of zoledronic acid preserved renal function and may be ...!-->!-->
ALEX’S LEMONADE STAND FOUNDATION (ALSF) has announced the opening of the first-of-its-kind Childhood Cancer Data Lab (CCDL) with the mission of accelerating cures. ALSF first announced the CCDL at the National Cancer Moonshot Summit in Washington, DC, hosted by former Vice President...!-->!-->
ALTHOUGH THE National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) strongly influence the management of advanced prostate cancer, they do not always reflect actual clinical practice. It turns out that in the real world, there are...!-->!-->!-->!-->
AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued by Hesketh et al in the Journal of Clinical Oncology,1 provides new evidence-based information on the appropriate use of olanzapine, neurokinin 1 (NK1) ...!-->!-->
NIVOLUMAB (OPDIVO) has been found to produce durable responses in patients with advanced hepatocellular carcinoma in the phase I/II CheckMate 040 trial. These findings were reported in The Lancet by Anthony B. El-Khoueiry, MD, of USC Norris Comprehensive Cancer Center, and...!-->!-->
PRIMARY LIVER CANCER is the second leading cause of cancer-related death worldwide. Hepatocellular carcinoma accounts for 90% of liver cancer, with around 800,000 new cases diagnosed globally each year.1 In contrast to the stable or declining trends observed for most neoplasms, the...!-->!-->
STAND UP TO CANCER (SU2C) and Lustgarten Foundation for Pancreatic Cancer Research are supporting a new translational research team to explore how chimeric antigen receptor (CAR) T-cell therapy can be applied to pancreatic cancer. The approach uses specially modified immune cells to...!-->!-->!-->!-->!-->!-->
AS REPORTED by Joseph Chin, MD, of London Health Sciences Centre, London, Ontario, and colleagues in the Journal of Clinical Oncology, ASCO and Clinical Care Ontario (CCO) have issued a joint update to the prior CCO guideline on use of brachytherapy in patients with prostate cancer.1,2...!-->!-->!-->!-->
BRACHYTHERAPY HAS a long track record in treating cancer, dating back to the first reported use of an implanted radioactive source in 1901, and brachytherapy for the treatment of prostate cancer dates back to 1914, when Pasteu and Degrais used a radium source inserted through a urethral...!-->!-->!-->!-->
ON JULY 1, Patricia Ganz, MD, assumed editorial leadership of JNCI: Journal of the National Cancer Institute. As Editor-in-Chief, she is also responsible for JNCI Monographs.
Dr. Ganz is Director of Cancer Prevention & Control Research at the University of California Los Angeles (UCLA)’s ...!-->!-->
CARLOS L. ARTEAGA, MD, has been named Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at The UT Southwestern Medical Center in Dallas.
Roles and Research at Vanderbilt
DR. ARTEAGA IS CURRENTLY Director of the Center for Cancer Targeted...!-->!-->
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.3 million in grants and awards to 247 promising oncology researchers at the 2017 ASCO Annual Meeting. CCF and ASCO congratulate the recipients on their contributions to the field of oncology and offer their profound thanks to...!-->!-->
BY CREATING an online fundraising campaign page at WeConquerCancer.org, anyone can make a difference in raising awareness and providing support for vitally important cancer research and education. A campaign might:
LEADING NATIONAL cancer organizations have released a joint position statement1 to guide the future of cancer health disparities research. The statement represents a unified strategy by ASCO, the American Association for Cancer Research, the American Cancer Society, and the National Cancer...
ASCO RECENTLY issued a position statement on rising cancer drug prices. The statement, asserting that solutions to address the affordability of cancer drugs must also preserve patients’ access to care and foster innovation, analyzes a wide array of options and recommends that a panel of...
ASCO’S BOOKLET Managing Your Weight After a Cancer Diagnosis: A Guide for Patients and Families addresses how being obese or overweight can slow recovery and affect survival.
Readers will find information on different weight loss methods, common challenges to losing weight and maintaining...!-->!-->
THE NONPROFIT Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) has released a new online resource called the Expanded Access Navigator. The website, which focuses on oncology, features the first pharmaceutical company directory of expanded access policies and criteria, as...
UNIVERSITY HOSPITALS (UH) has announced the appointment of Theodoros N. Teknos, MD, as the new President and Scientific Officer of UH Seidman Cancer Center, effective October 1. He will take over from current UH Seidman President Nathan Levitan, MD, who has been in the position since 2008 and...!-->!-->
AS REPORTED in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center and Harvard Medical School, and colleagues, the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan has been found to produce durable responses in patients ...!-->!-->
IN A SINGLE-ARM multicenter trial reported by Bardia and colleagues1 and reviewed in this issue of The ASCO Post, the use of sacituzumab govitecan (IMMU-132) showed a response rate of 30% and a clinical benefit rate of 46% in heavily pretreated patients with metastatic...!-->!-->
RECENTLY ANNOUNCED DATA from the phase III FLAURA trial showed a statistically significant and clinically meaningful progression-free survival benefit with osimertinib (Tagrisso) compared to current first-line standard-of-care treatment (erlotinib [Tarceva] or gefitinib [Iressa]) in previously...
THE WISTAR INSTITUTE has announced the appointment of scientist, medical oncologist, and National Academy of Medicine member Chi Van Dang, MD, PhD, as Professor.
Dr. Dang, the Scientific Director of the Ludwig Institute for Cancer Research in New York, shapes scientific strategy at Ludwig,...!-->!-->
Triple-negative breast cancer has a reputation for being a particularly challenging malignancy, but breast cancer specialist Nancy Davidson, MD, Senior Vice President of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, Seattle, put this in perspective in a recent...
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on patients with stage II or III colorectal cancer. These studies highlight dietary intervention, supplements, immunotherapy, combination chemotherapy, neoadjuvant therapy, and...
This past fall, the Fred Hutchinson Cancer Research Center in Seattle opened an all-encompassing 9,222-square foot outpatient cellular immunotherapy clinic, specifically designed to serve patients participating in the center’s novel immunotherapy clinical trials, which mainly focus on chimeric...
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
The following essay by Hope S. Rugo, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org.
I was in...
Claire Verschraegen, MD, has been appointed Director of the Division of Medical Oncology and Associate Director of the Translational Research Program at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute...!-->!-->
Two years ago, I was on my way to hospice care after numerous treatments, including surgery, chemotherapy, and radiation therapy failed to stop the progression of my stage IV castration-resistant prostate cancer. A last-minute call from my oncologist about a phase I trial of...!-->!-->
Robert L. Ferris, MD, PhD, an expert in immunotherapy and a specialist in head and neck cancer, has been named Director of the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center. His appointment was effective July 1.
Dr. Ferris, a 15-year veteran of the UPMC Hillman Cancer...!-->!-->
The U.S. Food and Drug Administration (FDA) recently granted approval, expanded approval, and breakthrough therapy designation to numerous treatments across a range of tumor types and malignancies.
New Drug Approvals
Daunorubicin-Cytarabine Combination (Vyxeos): On August 3, the FDA granted...
Angela H. Brodie, PhD, a pioneer in breast cancer research, passed away on June 7, 2017, from complications of Parkinson’s disease and pancreatic cancer. An obituary for Dr. Brodie was published previously in the June 25, 2017, issue of The ASCO Post. Here, Dr. Balkees Abderrahman shares a...
The Pain & Palliative Care Program at Fox Chase Cancer Center is offering a new Hospice and Palliative Medicine fellowship in partnership with the Hospice of the Visiting Nurse Association of Greater Philadelphia and Temple University Hospital. The 1-year program is approved by the...!-->!-->
Older adults continue to be proportionally underrepresented in oncology clinical trials, but the participation rate of adults aged 65 and older is increasing by “slow, incremental changes,” Stuart M. Lichtman, MD, noted in an interview with The ASCO Post. Prompting those changes are the rapidly...
Salk Institute for Biological Studies Professor Reuben Shaw, PhD, has received the National Cancer Institute (NCI) Outstanding Investigator Award, which encourages cancer research with breakthrough potential. Dr. Shaw, a member of Salk’s Molecular and Cell Biology Laboratory and holder of the...!-->!-->
According to a study by Heath D. Skinner, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck...!-->!-->
A phase II trial has shown that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinst) produces responses in brain metastases in patients with BRAF V600–mutant melanoma. These findings were reported by Michael A. Davies, MD, of The University of...!-->!-->
OSIMERTINIB (TAGRISSO) showed encouraging results as first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) in the phase III FLAURA trial, according to results presented at the 2017 European Society for Medical Oncology ...!-->!-->